Kazia Therapeutics (Cantrixil) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Kazia Therapeutics (Cantrixil) General Information

Description

Portfolio of global development rights for Cantrixil. The asset is used for the treatment of ovarian cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Uppsala
  • Sweden
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Corporate Office
  • Uppsala
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kazia Therapeutics (Cantrixil) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kazia Therapeutics (Cantrixil)‘s full profile, request access.

Request a free trial

Kazia Therapeutics (Cantrixil) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kazia Therapeutics (Cantrixil)‘s full profile, request access.

Request a free trial

Kazia Therapeutics (Cantrixil) FAQs

  • Where is Kazia Therapeutics (Cantrixil) headquartered?

    Kazia Therapeutics (Cantrixil) is headquartered in Uppsala, Sweden.

  • What industry is Kazia Therapeutics (Cantrixil) in?

    Kazia Therapeutics (Cantrixil)’s primary industry is Buildings and Property.

  • Is Kazia Therapeutics (Cantrixil) a private or public company?

    Kazia Therapeutics (Cantrixil) is a Private company.

  • What is the current valuation of Kazia Therapeutics (Cantrixil)?

    The current valuation of Kazia Therapeutics (Cantrixil) is .

  • What is Kazia Therapeutics (Cantrixil)’s current revenue?

    The current revenue for Kazia Therapeutics (Cantrixil) is .

  • Who are Kazia Therapeutics (Cantrixil)’s investors?

    Kazia Therapeutics has invested in Kazia Therapeutics (Cantrixil).

  • When was Kazia Therapeutics (Cantrixil) acquired?

    Kazia Therapeutics (Cantrixil) was acquired on 29-Mar-2021.

  • Who acquired Kazia Therapeutics (Cantrixil)?

    Kazia Therapeutics (Cantrixil) was acquired by Vivesto.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process